Your session is about to expire
← Back to Search
Other
Hyperbaric oxygen therapy-TBI for Post-Traumatic Brain Injury Syndrome
Phase 1
Waitlist Available
Led By Paul G Harch, M.D.
Research Sponsored by Paul G. Harch, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Adults or children with traumatic brain injury at least one year old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after the final hbot
Awards & highlights
No Placebo-Only Group
Summary
Hypothesis: That SPECT brain imaging tracks and is consistent with clinical improvements in patients receiving hyperbaric oxygen therapy (HBOT) for chronic traumatic brain injury.
Eligible Conditions
- Post-Traumatic Brain Injury Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ after completion of hbot
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after completion of hbot
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
SPECT brain imaging
Secondary study objectives
Cognitive testing
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Hyperbaric oxygen therapy-TBIExperimental Treatment1 Intervention
Low pressure hyperbaric oxygen therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hyperbaric oxygen therapy
2013
Completed Phase 3
~1500
Find a Location
Who is running the clinical trial?
Harch Hyperbaric Research FoundationOTHER
3 Previous Clinical Trials
130 Total Patients Enrolled
Paul G. Harch, M.D.Lead Sponsor
4 Previous Clinical Trials
160 Total Patients Enrolled
Paul G Harch, M.D.Principal InvestigatorLSU School of Medicine, New Orleans
4 Previous Clinical Trials
160 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger